Excelsior Biopharma Inc. (TPEX:6496)
25.00
+0.10 (0.40%)
Aug 19, 2026, 1:30 PM CST
Excelsior Biopharma Revenue
Excelsior Biopharma had revenue of 232.49M TWD in the quarter ending June 30, 2026, with 15.10% growth. This brings the company's revenue in the last twelve months to 936.92M, up 7.59% year-over-year. In the year 2025, Excelsior Biopharma had annual revenue of 898.26M with 4.22% growth.
Revenue (ttm)
936.92M
Revenue Growth
+7.59%
P/S Ratio
1.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.16B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 898.26M | 36.35M | 4.22% |
| Dec 31, 2024 | 861.91M | 90.35M | 11.71% |
| Dec 31, 2023 | 771.56M | 99.80M | 14.86% |
| Dec 31, 2022 | 671.76M | -666.63M | -49.81% |
| Dec 31, 2021 | 1.34B | -105.27M | -7.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.40B |
| Prince Pharmaceutical | 1.06B |
| Anxo Pharmaceutical | 878.88M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Winston Medical Supply | 632.80M |
| General Biologicals | 215.74M |
| Mediera | 195.89M |